image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
Discussion of Initial NX-2127 Phase 1a PK/ PD Data
October 27, 2021 at 8:30 AM EDT
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR